IDYA

Ideaya Biosciences Inc

IDYA, USA

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

https://www.ideayabio.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IDYA
stock
IDYA

Ideaya Biosciences Advances with IDE892 Study Targeting MTAP-Deleted Tumors TipRanks

Read more →
IDYA
stock
IDYA

IDEAYA Biosciences Faces Collaboration Termination by GSK TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$49.4706

Analyst Picks

Strong Buy

10

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

2.79

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

10.92 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very High

10.06 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

68.41 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 133.99% of the total shares of Ideaya Biosciences Inc

1.

FMR Inc

(14.9894%)

since

2025/06/30

2.

BlackRock Inc

(10.0893%)

since

2025/06/30

3.

Capital Research Global Investors

(7.4765%)

since

2025/06/30

4.

HHG PLC

(7.0812%)

since

2025/06/30

5.

American Funds SMALLCAP World A

(6.6971%)

since

2025/06/30

6.

Fidelity Growth Compy Commingled Pl S

(6.5514%)

since

2025/07/31

7.

Point72 Asset Management, L.P.

(5.7372%)

since

2025/06/30

8.

Vanguard Group Inc

(5.6387%)

since

2025/06/30

9.

Federated Hermes Inc

(5.2796%)

since

2025/06/30

10.

Fidelity Growth Company Fund

(4.6686%)

since

2025/07/31

11.

Deerfield Management Co

(4.4673%)

since

2025/06/30

12.

State Street Corp

(3.8631%)

since

2025/06/30

13.

Logos Global Management LP

(3.8166%)

since

2025/06/30

14.

Federated Hermes Kaufmann R

(3.083%)

since

2025/06/30

15.

Federated Hermes Kaufmann Growth

(3.083%)

since

2025/06/30

16.

Vanguard Total Stock Mkt Idx Inv

(2.9334%)

since

2025/07/31

17.

Sofinnova Ventures

(2.4506%)

since

2025/06/30

18.

Baker Bros Advisors LP

(2.4174%)

since

2025/06/30

19.

Geode Capital Management, LLC

(2.4111%)

since

2025/06/30

20.

iShares Russell 2000 ETF

(2.3086%)

since

2025/08/31

21.

T. Rowe Price Associates, Inc.

(2.1735%)

since

2025/06/30

22.

Federated Hermes Kaufmann Small Cap Grow

(2.1108%)

since

2025/06/30

23.

Federated Hermes Kaufmann Small Cap A

(2.1108%)

since

2025/06/30

24.

Citadel Advisors Llc

(2.0833%)

since

2025/06/30

25.

Pictet Asset Manangement SA

(2.0596%)

since

2025/06/30

26.

Fiera Capital Corporation

(1.7483%)

since

2025/06/30

27.

Morgan Stanley - Brokerage Accounts

(1.6583%)

since

2025/06/30

28.

SPDR® S&P Biotech ETF

(1.5297%)

since

2025/08/31

29.

Fidelity Growth Company K6

(1.4714%)

since

2025/07/31

30.

Adage Capital Partners Gp LLC

(1.4126%)

since

2025/06/30

31.

Goldman Sachs Group Inc

(1.4013%)

since

2025/06/30

32.

Fidelity Series Growth Company

(1.3036%)

since

2025/07/31

33.

US Small-Cap Growth II Equity Comp

(1.203%)

since

2025/06/30

34.

Pictet-Biotech P USD

(1.0972%)

since

2025/05/31

35.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0719%)

since

2025/07/31

36.

Fidelity Small Cap Index

(0.96%)

since

2025/06/30

37.

Janus Henderson Global Life Sciences D

(0.8997%)

since

2025/06/30

38.

Janus Henderson Global Life Sciences

(0.8997%)

since

2025/06/30

39.

Eventide Healthcare & Life Sciences I

(0.8807%)

since

2025/06/30

40.

Janus Henderson US SMID Cap Growth

(0.8678%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.8633

Latest Release

Date

2025-09-30

EPS Actual

1.33

EPS Estimate

-0.55

EPS Difference

1.88

Surprise Percent

341.8182%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(4)
Quality
High Quality(9)
Value
Undervalued(8.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.